Cortagen is a short synthetic peptide from the Khavinson "bioregulator" family, proposed as a tissue-specific regulator of nervous tissue. This page describes hypothesized and investigational ideas, not established treatments.
Overview
Cortagen is discussed within a framework that proposes very short peptides can act as tissue-specific regulators. Among these bioregulators, Cortagen is the one linked to the brain, and specifically the cerebral cortex. Most interest therefore centres on hypothesized effects relevant to nervous tissue:
- Proposed signalling toward neurons and cortical tissue.
- Hypothesized neuroprotective and neurotrophic-adjacent themes.
- Suggested relevance to neural recovery and regeneration in experimental reports.
These are the ideas researchers have explored; they are not a promise of any specific cognitive, neurological, or clinical result.
Cerebral cortex and neuroprotection focus
The distinguishing feature of Cortagen within the bioregulator family is its proposed affinity for nervous tissue. Discussions frame it around the idea that a peptide might help support neurons in the cortex, particularly under conditions of stress, injury, or aging. This tissue-specific, neuroprotection-oriented framing is central to how proponents describe it.
The bioregulator concept
The broader Khavinson model hypothesizes that short peptides interact with tissue-specific pathways and influence gene expression in a targeted way. Cortagen is presented as the neural member of that set. It is worth stressing that this is a proposed conceptual model rather than a mechanism that has been confirmed by robust, independent human research.
How Cortagen fits among bioregulators
Cortagen is usually discussed alongside other tissue-targeted peptides in the same family, each said to focus on a different organ:
- Chonluten — associated with the bronchopulmonary system.
- Crystagen — associated with immune-system regulation.
- Cortagen — associated with the brain and cerebral cortex.
The distinction between these peptides is one of proposed target tissue, not of demonstrated clinical outcome.
Evidence and caveats
Enthusiasm around Cortagen runs well ahead of the evidence. Key caveats:
- It is not an FDA-approved therapy in the United States.
- Supporting studies are mostly older, small, and Russian, with little independent replication.
- Hypothesized neuroprotective effects have not been confirmed in large controlled trials.
- Long-term safety in healthy people has not been established.